[Thyroid malignant lymphoma].
Noh
Jaeduk Yoshimura
JY
Ito Hospital.
Shimizu
Taeko
T
Ito
Koichi
K
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003581:Cytodiagnosis; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008223:Lymphoma / Q000145:classification / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D011878:Radiotherapy; D000069283:Rituximab; D013961:Thyroid Gland / Q000000981:diagnostic imaging / Q000473:pathology; D013964:Thyroid Neoplasms / Q000145:classification / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D014463:Ultrasonography; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone